Skip to content

Poseida Therapeutics, Inc.

CIK 0001661460

← back to feed
Revenue (TTM)
$135.22M
−50.4% YoY Q3 Nov 2024
Net Income (TTM)
−$67.19M
−92.9% YoY Q3 Nov 2024
EPS Diluted (TTM)
−$0.71
−53.9% YoY Q3 Nov 2024
Gross Margin
—
Q3 Nov 2024
Operating Margin
-53.8%
Q3 Nov 2024
Net Margin
-49.7%
Q3 Nov 2024
Free Cash Flow (TTM)
−$145.65M
Q3 Nov 2024
Cash
$49.34M
Q3 Nov 2024
Total Debt
$61.91M
Q3 Nov 2024
Shares Outstanding
97.47M sh
Q3 Nov 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings